Menu Icon

PRIVACY STATEMENT

When you browse the ASCENIV™ Website your personal information is not revealed to us. Details such as your name and e-mail address remain anonymous. As usual with virtually all web pages, the only initial information recorded is your IP address, which helps us to administer our Website and identify broad demographic information, such as your browser type and geographic location.

ADMA Biologics collects personally identifiable information, such as names, addresses, e-mail addresses and the like, only when voluntarily provided by a Website user. ADMA Biologics does not want to receive confidential, proprietary or personal medical information through Website communications.

Any communication with ASCENIV™ Website or any other e-mail transmission to ADMA Biologics on this Website is non-confidential. ADMA Biologics has no obligation to refrain from reproducing, publishing or otherwise using third party information for any purpose, and ADMA Biologics may use the content of any such communication, including any ideas or know how disclosed therein for ADMA Biologics' own commercial purposes. Whoever transmits any communication to this Website or otherwise to ADMA Biologics is solely responsible for its accuracy and completeness. This site is intended to provide a service to users.

All rights not expressly granted herein are reserved to ADMA Biologics.

Indication

ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

 

Important Safety Information for ASCENIV™

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

  • Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IVIG products in predisposed patients.
  • Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.